BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy Aug 9 Written by Yihang Chen Yihang Chen Previous Previous China's Biotech Financing Was Already Changing. What Will COINS Add? Next Next From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?
BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy Aug 9 Written by Yihang Chen Yihang Chen